Drug Profile

Research programme: antibody boron conjugate radiopharmaceuticals - TAE Life Sciences

Latest Information Update: 17 Jul 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator TAE Life Sciences
Class Antineoplastics; Drug conjugates; Radioisotopes; Radiopharmaceuticals
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Cancer

Highest Development Phases

Research Solid tumours

Most Recent Events

17 Jul 2023 Early research in Solid tumours in USA (IV) (TAE Life Sciences pipeline, July 2023)
22 Jun 2020 Antibody boron conjugate radiopharmaceuticals - TAE Life Sciences is available for licensing as of 22 Jun 2020. https://taelifesciences.com/contact/
02 Jun 2020 Early research in Cancer in USA (unspecified route), before June 2020

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com